MedTrace Logo

Dapagliflozin in Pulmonary Arterial Hypertension

NCT05179356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-01-21

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension

Conditions

Interventions

DRUG

Dapagliflozin 10 MG [Farxiga]

Dapagliflozin 10 mg given once daily for three months

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Mads Ersbøll

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-01-13
Completion
2026-01-13

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179356 on ClinicalTrials.gov